# Exemption and Exclusion From Certain Requirements of the Drug Supply Chain Security Act for the Distribution of FDA-Approved Naloxone Products During the Opioid Public Health Emergency Guidance for Industry – FDA Guidance

Source: https://www.keypedia.com/guidances/guidance-document/exemption-and-exclusion-from-certain-requirements-of-the-drug-supply-chain-security-act-for-the-distribution-of-fda-approved-naloxone-products-during-the-opioid-public-health-emergency-guidance-for-industry/d210019a-9b7e-4dde-8567-15304071541d

> FDA guidance document: Exemption and Exclusion From Certain Requirements of the Drug Supply Chain Security Act for the Distribution of FDA-Approved Naloxone Products During the Opioid Public Health Emergency Guidance for Industry. Issue date: September 22, 2022. Get complete insights and analysis.

---

## Details

- Title: Exemption and Exclusion From Certain Requirements of the Drug Supply Chain Security Act for the Distribution of FDA-Approved Naloxone Products During the Opioid Public Health Emergency Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2022-09-22
- Last Changed: 2022-09-22
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2022-D-1847">FDA-2022-D-1847</a>

## Related Documents

- [Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates:  Guidance for Industry](https://www.keypedia.com/guidances/guidance-document/temporary-policies-for-compounding-certain-starter-parenteral-nutrition-drug-products-for-neonates-guidance-for-industry/71f86ab2-1631-4c36-9ba5-e279181d0baf)
- [Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act--Compliance Policies](https://www.keypedia.com/guidances/guidance-document/enhanced-drug-distribution-security-requirements-under-section-582g1-of-the-federal-food-drug-and-cosmetic-act-compliance-policies/81e414c7-4ee9-4a96-aba3-257bbafce4bd)
- [Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization](https://www.keypedia.com/guidances/guidance-document/development-of-monoclonal-antibody-products-targeting-sars-cov-2-for-emergency-use-authorization/0146d188-0350-4f83-b103-4193b8be1e41)